

# Maristella Saponara

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7523135/publications.pdf>

Version: 2024-02-01

71  
papers

1,682  
citations

279701

23  
h-index

315616

38  
g-index

72  
all docs

72  
docs citations

72  
times ranked

2429  
citing authors

#	ARTICLE	IF	CITATIONS
1	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. <i>European Journal of Cancer</i> , 2022, 170, 10-16.	1.3	11
2	Course of Sars-CoV2 Infection in Patients with Cancer Treated with anti-PD-1: A Case Presentation and Review of the Literature. <i>Cancer Investigation</i> , 2021, 39, 9-14.	0.6	12
3	Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune Evasion. <i>Clinical Cancer Research</i> , 2021, 27, 4311-4324.	3.2	44
4	Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma. <i>European Journal of Cancer</i> , 2021, 157, 250-258.	1.3	52
5	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	5.1	73
6	SDHA Germline Variants in Adult Patients With SDHA-Mutant Gastrointestinal Stromal Tumor. <i>Frontiers in Oncology</i> , 2021, 11, 778461.	1.3	4
7	Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19. <i>Seminars in Oncology</i> , 2020, 47, 302-304.	0.8	15
8	Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097700.	1.4	6
9	Targeted Deep Sequencing Uncovers Cryptic KIT Mutations in KIT/PDGFR $\alpha$ /SDH/RAS-P Wild-Type GIST. <i>Frontiers in Oncology</i> , 2020, 10, 504.	1.3	16
10	Diagnostic Accuracy of Cardiac Computed Tomography and 18-F Fluorodeoxyglucose Positron Emission Tomography in Cardiac Masses. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2400-2411.	2.3	40
11	Genetic aberrations and molecular biology of cardiac sarcoma. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091849.	1.4	13
12	Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation. <i>Frontiers in Immunology</i> , 2020, 11, 851.	2.2	10
13	Primary malignant pericardial tumour in Lynch syndrome. <i>BMC Cancer</i> , 2020, 20, 191.	1.1	3
14	Recurrent Uterine Smooth-Muscle Tumors of Uncertain Malignant Potential (STUMP): State of The Art. <i>Anticancer Research</i> , 2020, 40, 1229-1238.	0.5	20
15	Complete radiological response to first-line regorafenib in a patient with abdominal relapse of BRAF V600E mutated GIST. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092730.	1.4	4
16	Paratesticular Mesenchymal Malignancies: A Single-Center Case Series, Clinical Management, and Review of Literature. <i>Integrative Cancer Therapies</i> , 2020, 19, 153473541990055.	0.8	5
17	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST) shows gene expression patterns associated to immune checkpoint inhibitors response. <i>Oncolmmunology</i> , 2019, 8, e1617588.	2.1	41
18	Granular cell tumor of the trachea as a rare cause of dyspnea in a young woman. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100961.	0.2	4

#	ARTICLE	IF	CITATIONS
19	Gain of FGF4 is a frequent event in KIT/PDGFR $\alpha$ /SDH/RAS $\pm$ WT GIST. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 636-642.	1.5	22
20	Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFR $\alpha$ mutation in a metastatic GIST patient responding to imatinib. <i>Scientific Reports</i> , 2019, 9, 2172.	1.6	5
21	An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. <i>Pharmacogenomics Journal</i> , 2019, 19, 390-400.	0.9	20
22	Current status of the adjuvant therapy in uterine sarcoma: A literature review. <i>World Journal of Clinical Cases</i> , 2019, 7, 1753-1763.	0.3	34
23	Successful multidisciplinary clinical approach and molecular characterization by whole transcriptome sequencing of a cardiac myxofibrosarcoma: A case report. <i>World Journal of Clinical Cases</i> , 2019, 7, 3018-3026.	0.3	7
24	Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor. <i>Anti-Cancer Drugs</i> , 2018, 29, 589-595.	0.7	10
25	Whole Exome Sequencing Uncovers Germline Variants of Cancer-Related Genes in Sporadic Pheochromocytoma. <i>International Journal of Genomics</i> , 2018, 2018, 1-9.	0.8	4
26	18F-FDG-PET/CT imaging in cardiac tumors: illustrative clinical cases and review of the literature. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591879356.	1.4	28
27	A Single-Centre Experience on the Management of Adenosarcoma: A Successful Report of an Integrated Medical and Surgical Approach. <i>Clinical Medicine Insights: Oncology</i> , 2018, 12, 117955491878247.	0.6	4
28	Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. <i>International Journal of Molecular Sciences</i> , 2018, 19, 732.	1.8	29
29	Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1855.	1.8	4
30	Immune microenvironment profiling of gastrointestinal stromal tumors (GIST).. <i>Journal of Clinical Oncology</i> , 2018, 36, 11534-11534.	0.8	1
31	Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST. <i>Molecular Cancer Research</i> , 2017, 15, 553-562.	1.5	53
32	Pharmacological therapies for Liposarcoma. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 361-377.	1.3	17
33	An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure. <i>Angiogenesis</i> , 2017, 20, 139-148.	3.7	10
34	<sc>HSPA</sc>8 as a novel fusion partner of <sc>NR</sc>4<sc>A</sc>3 in extraskeletal myxoid chondrosarcoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 582-586.	1.5	38
35	(Neo)adjuvant treatment in localised soft tissue sarcoma: The unsolved affair. <i>European Journal of Cancer</i> , 2017, 70, 1-11.	1.3	37
36	Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice. <i>Therapeutic Advances in Medical Oncology</i> , 2017, 9, 731-739.	1.4	20

#	ARTICLE	IF	CITATIONS
37	Identification of SRF-E2F1 fusion transcript in EWSR-negative myoepithelioma of the soft tissue. <i>Oncotarget</i> , 2017, 8, 60036-60045.	0.8	17
38	What is changing in the surgical treatment of gastrointestinal stromal tumors after multidisciplinary approach? A comprehensive literature's review. <i>Minerva Surgery</i> , 2017, 72, 219-236.	0.1	5
39	Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors. <i>Anti-Cancer Drugs</i> , 2016, 27, 353-363.	0.7	5
40	The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 473-484.	1.1	7
41	Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome. <i>Tumor Biology</i> , 2016, 37, 13413-13423.	0.8	19
42	Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors. <i>Epigenomics</i> , 2016, 8, 1347-1366.	1.0	23
43	Whole exome sequencing (WES) on formalin-fixed, paraffin-embedded (FFPE) tumor tissue in gastrointestinal stromal tumors (GIST). <i>BMC Genomics</i> , 2015, 16, 892.	1.2	48
44	Good survival outcome of metastatic SDH-deficient gastrointestinal stromal tumors harboring SDHA mutations. <i>Genetics in Medicine</i> , 2015, 17, 391-395.	1.1	41
45	Molecular characterization of metastatic exon 11 mutant gastrointestinal stromal tumors (GIST) beyond KIT/PDGFR $\pm$ genotype evaluated by next generation sequencing (NGS). <i>Oncotarget</i> , 2015, 6, 42243-42257.	0.8	20
46	Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours. <i>Oncology Letters</i> , 2014, 8, 1793-1799.	0.8	6
47	Integrated genomic study of quadruple-WT GIST (KIT/PDGFR $\alpha$ /SDH/RAS pathway wild-type GIST). <i>BMC Cancer</i> , 2014, 14, 685.	1.1	70
48	Treatments for gastrointestinal stromal tumors that are resistant to standard therapies. <i>Future Oncology</i> , 2014, 10, 2045-2059.	1.1	10
49	Dystrophin deregulation is associated with tumor progression in KIT/PDGFR $\alpha$ mutant gastrointestinal stromal tumors. <i>Clinical Sarcoma Research</i> , 2014, 4, 9.	2.3	9
50	Analysis of all subunits, SDHA, SDHB, SDHC, SDHD, of the succinate dehydrogenase complex in KIT/PDGFR $\alpha$ wild-type GIST. <i>European Journal of Human Genetics</i> , 2014, 22, 32-39.	1.4	90
51	Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. <i>World Journal of Gastroenterology</i> , 2014, 20, 7049.	1.4	22
52	Integrate whole genomic study of KIT/PDGFR $\alpha$ wild-type (WT) GIST. <i>Journal of Clinical Oncology</i> , 2014, 32, 10513-10513.	0.8	0
53	Surgical second-look in high risk gastrointestinal stromal tumor of small intestine: A case report. <i>International Journal of Surgery Case Reports</i> , 2013, 4, 7-10.	0.2	6
54	Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy. <i>Pharmacological Research</i> , 2013, 68, 1-6.	3.1	64

#	ARTICLE	IF	CITATIONS
55	Development of a Nephrotic Syndrome in a Patient with Gastrointestinal Stromal Tumor during a Long-Time Treatment with Sunitinib. <i>Case Reports in Oncology</i> , 2012, 5, 651-656.	0.3	7
56	Impressive long-term disease stabilization by nilotinib in two pretreated patients with KIT/PDGFR $\alpha$ wild-type metastatic gastrointestinal stromal tumours. <i>Anti-Cancer Drugs</i> , 2012, 23, 567-572.	0.7	16
57	Evaluation of Extensive Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 778-785.	1.2	63
58	Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. <i>BMC Cancer</i> , 2012, 12, 231.	1.1	44
59	Chronic therapy in gastrointestinal stromal tumours (GISTs): the big gap between theory and practice. <i>Targeted Oncology</i> , 2012, 7, 243-246.	1.7	5
60	Microscopic Margins of Resection Influence Primary Gastrointestinal Stromal Tumor Survival. <i>Oncology Research and Treatment</i> , 2012, 35, 645-648.	0.8	22
61	Duration of adjuvant treatment following radical resection of metastases from gastrointestinal stromal tumours. <i>Oncology Letters</i> , 2012, 3, 677-681.	0.8	5
62	Late recurrences of gastrointestinal stromal tumours (GISTs) after 5 years of follow-up. <i>Medical Oncology</i> , 2012, 29, 144-150.	1.2	7
63	Three cases of bone metastases in patients with gastrointestinal stromal tumors. <i>Rare Tumors</i> , 2011, 3, 51-53.	0.3	29
64	Differential expression of neural markers in KIT and PDGFR $\alpha$ wild-type gastrointestinal stromal tumours. <i>Histopathology</i> , 2011, 59, 1071-1080.	1.6	22
65	Successful radiotherapy for local control of progressively increasing metastasis of gastrointestinal stromal tumor. <i>Rare Tumors</i> , 2011, 3, 153-154.	0.3	18
66	A molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy number. <i>Laboratory Investigation</i> , 2010, 90, 1285-1294.	1.7	77
67	Management of Patients with Gastrointestinal Stromal Tumor in Clinical Practice in Italy: A Critical "Event Tree Model" Analysis of Decision-Making Processes and Outcomes. <i>Tumori</i> , 2010, 96, 219-228.	0.6	0
68	Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (Review). <i>Oncology Reports</i> , 2009, 21, 1359-66.	1.2	52
69	Insulin-like growth factor 1 receptor expression in wild-type GISTs: A potential novel therapeutic target. <i>International Journal of Cancer</i> , 2009, 125, 2991-2994.	2.3	70
70	Gastrointestinal stromal tumors: report of an audit and review of the literature. <i>European Journal of Cancer Prevention</i> , 2009, 18, 106-116.	0.6	45
71	Surgical debulking of gastrointestinal stromal tumors: Is it a reasonable option after second-line treatment with sunitinib?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 625-630.	1.2	21